Company profile
GI Cell, Inc.
Privately held: no public share price (Korean NK/T-cell immunotherapy company (gi-cell.com), developer of GIC-102 (T.O.P. NK) tested in multiple myeloma. Distinct from the similarly-named GI Innovation (KOSDAQ:358570) and GC Cell (KOSDAQ:144510) -- checked and confirmed as a separate entity. No public listing found for GI Cell itself; treated as private. Sources: https://clinicaltrials.gov/study/NCT05880043 ; https://api.gleif.org/api/v1/lei-records/2549000CDYS5YH6XDR52 ; https://api.gleif.org/api/v1/lei-records/984500EC7LEQEU100570 ; https://api.gleif.org/api/v1/lei-records/254900ESD9GZFY66OR92 ; https://api.gleif.org/api/v1/lei-records/549300NIGKDV9203Q946 ; https://api.gleif.org/api/v1/lei-records/5493007DSIFXCC6J0N24 Entity resolved by asset-pipeline-v2.)
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | Allogeneic (non-HLA-matched donor-derived) natural killer (NK) cellCell therapy | Multiple Myeloma |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.